Table 2 Baseline patient characteristics for all registered patients eligible to receive study drug (population 3), according to treatment allocation
| Â | LMWH (n = X) | Aspirin (n = X) |
|---|---|---|
Age (years) | xx.x (xx.x – xx.x), n | xx.x (xx.x – xx.x), n |
BMI (kg/m2) | xx.x (xx.x – xx.x), n | xx.x (xx.x – xx.x), n |
Male sex | n (%) | n (%) |
ASA grading | ||
1 | n (%) | n (%) |
2 | n (%) | n (%) |
3 | n (%) | n (%) |
4 | n (%) | n (%) |
5 | n (%) | n (%) |
Previous venous thromboembolism | n (%) | n (%) |
Long term anticoagulant use | Â | Â |
Aspirin | n (%) | n (%) |
Other single antiplatelet | n (%) | n (%) |
Joint replacement | ||
THA | n (%) | n (%) |
TKA | n (%) | n (%) |
Other HA | n (%) | n (%) |
Other KA | n (%) | n (%) |
Bilateral | n (%) | n (%) |
Type of surgery | Â | Â |
Primary total | n (%) | n (%) |
Primary partial | n (%) | n (%) |
Primary resurfacing | n (%) | n (%) |
Revision | n (%) | n (%) |
Other | n (%) | n (%) |
Indication | ||
Osteoarthritis | n (%) | n (%) |
Inflammatory | n (%) | n (%) |
Avascular necrosis | n (%) | n (%) |
Fracture | n (%) | n (%) |
Other | n (%) | n (%) |
Prosthesis | ||
Cemented | n (%) | n (%) |
Hybrid | n (%) | n (%) |
Uncemented | n (%) | n (%) |
Pain and function | ||
Oxford Hip Score | xx.x (xx.x – xx.x), n | xx.x (xx.x – xx.x), n |
Oxford Knee Score | xx.x (xx.x – xx.x), n | xx.x (xx.x – xx.x), n |
EQ-5D | xx.x (xx.x – xx.x), n | xx.x (xx.x – xx.x), n |
EQ-VAS | xx.x (xx.x – xx.x), n | xx.x (xx.x – xx.x), n |